How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,484 results for

Melasma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Efficacy and Safety of Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream in Chinese Patients with Melasma: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study. (Abstract)

Efficacy and Safety of Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream in Chinese Patients with Melasma: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study. This study aimed to determine the efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin (FAHT) cream for the treatment of moderate and severe facial melasma. The primary objective was assessment of clinical efficacy, instrumental measured efficacy, and integral therapeutic (...) efficacy at the end of weeks 4 and 8.A total of 233 subjects were randomly allocated (1:1 ratio) to receive topically administered FAHT cream (n = 117) or placebo (n = 116) once nightly for 8 weeks. Observed side effects were documented throughout.In the per protocol set (PPS; those subjects who met all requirements of the protocol), the integral therapeutic efficacy rate of FAHT cream on moderate and severe melasma was 68.57% (vs. placebo, 0.94%), the clinical effective rate of FAHT cream was 74.29

2015 Clinical drug investigation Controlled trial quality: predicted high

182. Overexpression of Tyrosine hydroxylase and Dopa decarboxylase associated with pupal melanization in Spodoptera exigua Full Text available with Trip Pro

Overexpression of Tyrosine hydroxylase and Dopa decarboxylase associated with pupal melanization in Spodoptera exigua Melanism has been found in a wide range of species, but the molecular mechanisms involved remain largely elusive. In this study, we studied the molecular mechanisms of the pupal melanism in Spodoptera exigua. The full length cDNA sequences of tyrosine hydroxylase (TH) and dopa decarboxylase (DDC), two key enzymes in the biosynthesis pathway of melanin, were cloned (...) , and their temporal expression patterns in the integument were compared during the larval-pupal metamorphosis process of the S. exigua wild type (SEW) and melanic mutant (SEM) strains. No amino acid change in the protein sequence of TH and DDC was found between the two strains. Both DDC and TH were significantly over-expressed in the integument of the SEM strain at late-prepupa and 0 h pupa, respectively, compared with those of the SEW strain. Feeding 5(th) instar larvae of SEM with diets incorporated with 1 mg/g

2015 Scientific reports

183. The histopathological characteristics of male melasma: Comparison with female melasma and lentigo. (Abstract)

The histopathological characteristics of male melasma: Comparison with female melasma and lentigo. Knowledge of the histopathology of melasma is a prerequisite for understanding its pathogenesis. However, the histopathological characteristics of male melasma are not well characterized.We sought to investigate the histopathological characteristics of melasma in men compared with those of women with melasma and solar lentigo.Biopsy specimens were obtained from both the lesional skin (...) and the adjacent nonlesional skin in 8 men with melasma, 10 women with melasma, and 5 men and women each with solar lentigo. The samples were stained using Fontana-Masson and Verhoeff-van Gieson. Immunohistochemistry for melanocytes, the estrogen receptor, progesterone receptor, factor VIIIa-related antigen, stem cell factor, and c-kit was performed.Increased vascularity was found in the lesion of male melasma. The lesion to nonlesion ratio of the vessel area was increased in male melasma compared with lentigo

2012 Journal of American Academy of Dermatology

184. Treatment of melasma (chloasma) by local application of a steroid cream. (Abstract)

Treatment of melasma (chloasma) by local application of a steroid cream. 15 patients with melasma were treated with betamethasone 17-valerate in a cream base containing DMSO. One patient with secondary pigmentation was also entered in the trial. In nine patients results were favourable and in three results were moderate. This effect could be ascribed to the steroid.

1975 Dermatologica Controlled trial quality: uncertain

185. Topical tranexamic acid as a promising treatment for melasma. (Abstract)

Topical tranexamic acid as a promising treatment for melasma. In recent times, tranexamic acid (TA) is claimed to have whitening effects especially for ultraviolet-induced hyperpigmentation including melasma. The aim of our study was to evaluate the efficacy and safety of topical solution of TA and compare it with combined solution of hydroquinone and dexamethasone as the gold standard treatment of melasma in Iranian women.This was a double-blind split-face trial of 12 weeks which was conducted (...) in Isfahan, Iran. Fifty Iranian melasma patients applied topical solution of 3% TA on one side of the face, and topical solution of 3% hydroquinone + 0.01% dexamethasone on the other side two times a day. The Melasma Area and Severity Index (MASI) and the side effects were evaluated at baseline and every 4 weeks before and after photographs to be compared by a dermatologist were taken. The patient satisfaction was documented at week 12.A repeated measurement analysis was used to evaluate the changes

2014 Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences Controlled trial quality: uncertain

186. Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma. (Abstract)

Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma. Melasma is a dermatosis with significant repercussions on patients' quality of life, and there is currently no standard treatment. Hydroquinone is deemed the treatment of choice, but its safety has been questioned in certain cases.To determine the efficacy and safety of a new combination of retinoids in the improvement of melasma.Prospective, double-blind, vehicle (...) -controlled, and randomized study in 30 patients with melasma. The product was applied on one side of the face and the vehicle on the other, twice daily during 3 months. Standardized photographs were taken using RBX technology on the three visits (basal, at one and a half months and at 3 months). The main variable to determine the efficacy was the improvement of the hemifacial Melasma Area Severity Index (MASI). Other variables were determined such as improvement perceived by the investigator, improvement

2014 Journal of cosmetic dermatology Controlled trial quality: uncertain

187. Evaluation of efficacy of cysteamine cream in the treatment of epidermal melasma: a randomized double blind placebo controlled study\ (Abstract)

Evaluation of efficacy of cysteamine cream in the treatment of epidermal melasma: a randomized double blind placebo controlled study\ Melasma is a difficult-to-treat hyperpigmentary disorder. While cysteamine is a known potent depigmenting agent, its efficacy in treating melasma has not been tested.To study the efficacy of cysteamine 5% cream in the treatment of patients with epidermal melasma.In this double-blind randomized study, participating patients (n = 50) received either placebo (n = 25 (...) ) or cysteamine cream (n = 25). Cysteamine cream or placebo were applied on the lesions once a day at bedtime over 4 months. The efficacy of treatments was determined through Mexameter skin colorimetry, Melasma Area Severity Index (MASI) score, Investigator's Global Assessment (IGA) and patients' questionnaires, all performed at baseline and after 2 and 4 months of treatment.At baseline, the mean differences between pigmented and normal skin (calculated by Mexameter) were 75.2 ± 37 and 68.9 ± 31

2014 The British journal of dermatology Controlled trial quality: predicted high

188. The efficacy in melasma treatment using a 1410 nm fractional photothermolysis laser. (Abstract)

The efficacy in melasma treatment using a 1410 nm fractional photothermolysis laser. Melasma treatment modalities including topical and procedural therapy have been employed with variable results and high recurrence rate.To quantitatively assess improvement in melasma and side effects after 1410 nm fractional photothermolysis laser treatments and to determine efficacy at 1-, 2- and 3-month follow-up after treatment.Thirty volunteers with melasma were treated with 1410 nm fractional (...) photothermolysis for four passes on full face and additional four passes on melasma area. They were randomly treated on one side of their face with 20 mJ at 5% coverage and the other side of their face with 20 mJ at 20% coverage. All subjects were treated monthly for five times. Melanin index, Visual analogue scale and Melasma Area and Severity Index score were measured at baseline and 1-, 2- and 3-month follow-up after complete treatment protocol.There was statistically significant improvement of Melanin

2014 Journal of the European Academy of Dermatology and Venereology : JEADV Controlled trial quality: uncertain

189. Melanic Facial Patterns and their Significance in the Multicolored Asian Lady Beetle (Harmonia axyridis) Full Text available with Trip Pro

Melanic Facial Patterns and their Significance in the Multicolored Asian Lady Beetle (Harmonia axyridis) The relationship between the patterns present on the pronotum and the elytron of the multicolored Asian lady beetle Harmonia axyridis was investigated. In males elytron size was a significant predictor of pronotal intensity and in females the fraction of the pronotum covered in black was related to their elytral spot brightness. Other significant sex differences included females having more

2014 The American midland naturalist

190. Effect of 82% Lactic Acid in Treatment of Melasma Full Text available with Trip Pro

Effect of 82% Lactic Acid in Treatment of Melasma Melasma is an acquired, chronic, and symmetrical hypermelanosis, characterized by brown patches of variable darkness on sun exposed areas of body. There are numerous modalities of treatment currently in use for this disease, of which the chemical peeling is very commonly used. Therefore, the present work was done to see the effect of 82% lactic acid peel in the treatment of melasma. A total number of 20 patients of either sex attending the OPD (...) of dermatology department with clinically evident melasma were included in the study. 82% Lactic acid peel was applied on the face for 12 weeks in each patient. Patients were evaluated clinically and photographically at various intervals and in follow-up till 24 weeks. Assessment of patient satisfaction and side effects were also noted. All the subjects completed the study. Application of this peel for 12 weeks significantly decreased the melasma area severity index score and also melasma severity scale

2014 International scholarly research notices

191. Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study

Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02095990

2014 Clinical Trials

192. Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma

Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02095756 Recruitment Status : Completed First Posted : March 26, 2014 Last Update Posted : July 31, 2015

2014 Clinical Trials

193. Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients. Full Text available with Trip Pro

Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients. We initially observed that the presence of circulating NY-ESO-1- and/or Melan-A-specific T cells in patients with stage IV melanoma was significantly associated with prolonged survival. Here, we report the ways in which the phenotypes and functions of these T cells differentially affect survival in patients preselected for NY-ESO-1 (...) and/or Melan-A reactivity.We assayed functional antigen-reactive T cells recognizing NY-ESO-1 and/or Melan-A after in vitro stimulation using overlapping peptide pools. After restimulation, we assayed six cytokines simultaneously by intracellular cytokine staining. This allowed us to analyze the functional antigen response of both CD4(+) and CD8(+) T cells at the single-cell level.We observed that NY-ESO-1 stimulated mainly CD4(+) T cells, whereas Melan-A more often stimulated CD8(+) T cells. NY-ESO-1

2014 Clinical Cancer Research

194. Combination Treatment of Low-Fluence 1,064-nm Q-Switched Nd: YAG Laser With Novel Intense Pulse Light in Korean Melasma Patients: A Prospective, Randomized, Controlled Trial. (Abstract)

Combination Treatment of Low-Fluence 1,064-nm Q-Switched Nd: YAG Laser With Novel Intense Pulse Light in Korean Melasma Patients: A Prospective, Randomized, Controlled Trial. Recently, intense pulsed light (IPL) and low-fluence Q-switched neodymium-doped yttrium aluminum (LF-QS-Nd:YAG) laser have been successfully used to treat melasma.To evaluate the effectiveness and safety of combined novel fractionated IPL (IPL-F) with LF-QS-Nd:YAG laser in patients with melasma.Twelve patients underwent 6 (...) treatment sessions of concomitant IPL-F and LF-QS-Nd:YAG laser (combination group), and 12 patients underwent 6 treatment session of IPL-F alone (IPL only group). Partial melasma area and severity index (MASI) scores were evaluated by 2 dermatologists using digital photography.In the combination group, the partial MASI score has significantly decreased by 47% at 1 month after the treatment (p < .05) and 50% at 2 months after the last treatment (p < .01). At 1 month and 2 months after the treatment

2014 Dermatologic Surgery Controlled trial quality: uncertain

195. Cadherin 11, a miR-675 Target, Induces N-cadherin Expression and Epithelial-Mesenchymal Transition in Melasma. Full Text available with Trip Pro

Cadherin 11, a miR-675 Target, Induces N-cadherin Expression and Epithelial-Mesenchymal Transition in Melasma. Cadherin 11 (CDH11) was identified as a target of miR-675 by using a luciferase reporter assay. CDH11 expression and miR-675 expression were inversely correlated. CDH11 expression was not detected in melanocytes, but CDH11 expression in fibroblasts and keratinocytes positively influenced melanogenesis via the canonical Wnt and AKT activation pathways in cocultured melanocytes. CDH11

2014 Journal of Investigative Dermatology

196. Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients. (Abstract)

Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients. Melasma is a common disorder of facial hyperpigmentation that is often resistant to treatment.To evaluate the efficacy of trichloroacetic acid (TCA) peeling in comparison with double frequency Q-switched neodymium-doped:yttrium aluminum garnet (QS-Nd:YAG) laser in the treatment of melasma.Sixty-five adult Egyptian female patients with melasma were enrolled in this study. Wood light (...) was used for determination of the histological type of melasma. The patients were divided into 4 groups according to treatment modalities: peeling with different concentrations of TCA and double frequency QS-Nd:YAG laser. Trichloroacetic acid peeling was performed every 2 weeks up to 8 sessions, whereas laser treatment was performed every month up to 6 sessions. Melasma area and severity index (MASI) score was used before and after treatment for evaluation.Improvement percentage of MASI score

2014 Dermatologic Surgery Controlled trial quality: uncertain

197. A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. (Abstract)

A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. Undecylenoyl phenylalanine is a novel skin-lightening agent, probably acting as α-melanocyte-stimulating hormone (α-MSH) and beta-adrenergic receptor (β-ADR) antagonist.The objective of this double-blind randomized comparative study was to evaluate the efficacy and safety of a preparation containing undecylenoyl phenylalanine 2% in the topical treatment (...) of melasma in females.Forty female patients with melasma were randomly assigned to apply either the active preparation or the vehicle alone, twice daily for 12 weeks. Patients were evaluated monthly for efficacy and safety.In all, 37 patients completed the study. Of the 20 patients on active treatment, no one responded completely, but 17 (85%) had partial response. Of them, 11 had moderate improvement and six had marked improvement. Lightening of the lesions was evident from the first follow-up visit

2014 Journal of cosmetic dermatology Controlled trial quality: uncertain

198. A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02110134 Recruitment Status : Completed First Posted : April 10, 2014 Last Update Posted : July 30, 2015 Sponsor: Cynosure, Inc. Information

2014 Clinical Trials

199. Prevention of Melasma Relapse During Summertime

Prevention of Melasma Relapse During Summertime Prevention of Melasma Relapse During Summertime - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prevention of Melasma Relapse During Summertime The safety (...) Clinique Applique a la Dermatologie Study Details Study Description Go to Brief Summary: Main objective is to show that a photoprotective sunscreen having a protection against the visible light is more effective than a sunscreen having the same UVA AND UVB protection but with a low (weak) protection against the visible, to prevent the relapses of the melasma during the summertime. Condition or disease Intervention/treatment Phase Melasma Other: Sunscream with visible light protection Other: Sunscream

2014 Clinical Trials

200. Therapeutic outcome of melasma treatment by dual-wavelength (511 and 578 nm) laser in patients with skin phototypes III-V. (Abstract)

Therapeutic outcome of melasma treatment by dual-wavelength (511 and 578 nm) laser in patients with skin phototypes III-V. Recent evidence suggests that vascular abnormalities are involved in the pathogenesis of melasma. Copper bromide (CuBr) laser, which emits dual wavelengths (511 and 578 nm), enabling simultaneous and selective destruction of melanin-containing cells and blood vessels, may be of benefit in the treatment of melasma.To investigate the efficacy and adverse effects (AEs) of CuBr (...) laser for melasma treatment in patients with skin phototypes III-V.We enrolled 24 Thai women with melasma to receive six CuBr laser treatments, 2 weeks apart. Objective (colour measurement) and subjective (clinical evaluation of photographs by three dermatologists blinded to the order of the photographs) assessments were obtained at baseline, after three and six treatments, and at the 3-month follow-up visit. A visual analogue scale (VAS) was used for patient assessment of change at baseline, after

2014 Clinical & Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>